OrganiGram Holdings Inc.

Organigram Holdings Inc. is a Canadian enterprise, operating through its subsidiaries, that cultivates, manufactures, and distributes cannabis and cannabis-derived products. Their medical division offers a range of medical cannabis, including dried flowers, oils, and vaporizers, for both civilian patients and military veterans. For the adult-use recreational market, the company provides diverse cannabis products, edibles, and concentrates, marketed under various brands such as Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour. Organigram also functions as a wholesaler, supplying cannabis plant cuttings, dried flowers, blends, pre-rolls, and derivative products to retailers and other distributors within the recreational cannabis sector. Consumers can acquire their products through online platforms and telephone orders. Organigram Holdings Inc. was established in 2013 and has its corporate headquarters in Moncton, Canada.

OrganiGram Holdings Inc. trades as OGI.TO on TSX. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $259.18M of revenue and -$24.76M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

OrganiGram Holdings Inc. can be compared against peers such as Aurora Cannabis Inc., Cipher Pharmaceuticals Inc., Medical Facilities Corporation, Eupraxia Pharmaceuticals Inc., Fennec Pharmaceuticals Inc., HLS Therapeutics Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $206.07M, beta of 1.84, and return on equity of -7.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

OGI.TO currently shows total debt of $8.75M and beta of 1.84. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.organigram.ca

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.